Elevance Health (ELV) reiterated its 2026 adjusted earnings per share (EPS) guidance of at least $27.00, citing strong operational execution and Q3 performance tracking ahead of expectations. The company’s Chief Financial Officer, Marc Kaye, highlighted that third-quarter results, which include July and August figures, reflect improved profitability across its diversified healthcare portfolio, including Medicare Advantage and employer group segments. Despite a noted trough in Medicaid margins in 2026, Kaye emphasized that 2027 is expected to see recovery, supported by broader business drivers rather than a single segment’s performance. Full-year benefit expense ratio guidance remained unchanged, underscoring disciplined cost management amid rising healthcare costs, particularly in independent dispute resolution (IDR) cases, where providers prevail in about 85% of cases at roughly eight times in-network rates. IDR contributed an estimated $15 billion to incremental healthcare spending in 2025 alone. The company also noted robust free cash flow of at least $6 billion in 2026 and a 7% yield, reflecting operational resilience. Key Medicare Advantage targets include an operating margin of at least 2% in 2026, with a long-term goal of 3% to 5%. Integration efforts with Carelon and CarelonRx have delivered mid-teens percentage savings per member per month, alongside reductions of 30% in emergency room visits and 10% in high-cost specialty drug administration. Recent exits from the District of Columbia and a Louisiana joint venture with Blue Cross and Blue Shield of Louisiana are set to conclude by year-end 2026. A final CMS resolution from July ensures uninterrupted Medicare Advantage plan offerings. Looking ahead, Kaye set a 2027 adjusted EPS growth target of at least 12% off the 2026 baseline, citing multiple operational levers across health benefits and Carelon, while the One Big Beautiful Bill Act—expected to begin affecting most states in January 2027—will introduce community engagement requirements.
Elevance Health Reaffirms 2026 EPS Guidance Amid Q3 Momentum
Health insurer maintains outlook on adjusted earnings despite Medicaid margin challenges and regulatory shifts ahead of 2027.
PA
Priya Anand · Equities & Earnings Desk · 20 Sept 2026 · 09:37 · 1 min de lecture
Cet article a été produit avec l'assistance de l'IA et édité par un journaliste de Finance Review Daily.
ADVERTISEMENT

PA
Par
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
Plus de Priya Anand →









